Experienced in Transient Erythroblastopenia of Childhood

Uma H. Athale

1200 Main St W,

Hamilton, CA

Clinical Trials:Currently Recruiting for 4 Trials

Experienced in Transient Erythroblastopenia of Childhood

1200 Main St W,

Hamilton, CA

OverviewLocationsClinical Research

Overview

Uma Athale practices in Hamilton, Canada. Ms. Athale is rated as an Experienced expert by MediFind in the treatment of Transient Erythroblastopenia of Childhood. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, L1 Syndrome, Hemoglobinopathy, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 90 peer reviewed articles and participating in 20 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Transient Erythroblastopenia of Childhood.

Gender

Female

Locations

1200 Main St W, Hamilton, L8N3Z5, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

Enrollment Status: Recruiting

Publish Date: October 10, 2025

Intervention Type: Drug, Procedure, Biological, Radiation

Study Drugs: Busulfan, Carboplatin, Cisplatin, Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Etoposide Phosphate, Isotretinoin, Melphalan Hydrochloride, Sargramostim, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate

Study Phase: Phase 3

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations

Enrollment Status: Recruiting

Publish Date: September 18, 2025

Intervention Type: Procedure, Other, Drug

Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Dexrazoxane, Etoposide, Gemtuzumab, Gilteritinib, Liposomal Daunorubicin, Liposomal Cytarabine, Methotrexate, Mitoxantrone, Hydrocortisone

Study Phase: Phase 3

Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Enrollment Status: Recruiting

Publish Date: September 18, 2025

Intervention Type: Radiation, Drug, Procedure

Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Topotecan, Vincristine

Study Phase: Phase 2

Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy

Enrollment Status: Recruiting

Publish Date: May 23, 2025

Intervention Type: Other

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)